Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2018, Article ID 3298378, 9 pages
Research Article

Saccharomyces cerevisiae-Derived Mannan Does Not Alter Immune Responses to Aspergillus Allergens

1Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN 38103, USA
2Children’s Foundation Research Institute, Memphis, TN 38103, USA

Correspondence should be addressed to Amali E. Samarasinghe; ude.cshtu@saramasa

Received 5 September 2017; Revised 3 November 2017; Accepted 7 November 2017; Published 1 January 2018

Academic Editor: Taiyoun Rhim

Copyright © 2018 D. Betty Lew et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Severe asthma with fungal sensitization predominates in the population suffering from allergic asthma, to which there is no cure. While corticosteroids are the mainstay in current treatment, other means of controlling inflammation may be beneficial. Herein, we hypothesized that mannan from Saccharomyces cerevisiae would dampen the characteristics of fungal allergic asthma by altering the pulmonary immune responses. Using wild-type and transgenic mice expressing the human mannose receptor on smooth muscle cells, we explored the outcome of mannan administration during allergen exposure on the pathogenesis of fungal asthma through measurement of cardinal features of disease such as inflammation, goblet cell number, and airway hyperresponsiveness. Mannan treatment did not alter most hallmarks of allergic airways disease in wild-type mice. Transgenic mice treated with mannan during allergen exposure had an equivalent response to non-mannan-treated allergic mice except for a prominent granulocytic influx into airways and cytokine availability. Our studies suggest no role for mannan as an inflammatory regulator during fungal allergy.